Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
SRPT · Nasdaq · United States · Pharmaceutical Preparations
In shortSarepta Therapeutics, Inc. is loss-making, burns cash and holds more cash than debt, with revenue growing (+15.6% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -31.8% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -32.5% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -53.5% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -28.1% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.32× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.73× | 71/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -2.78 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -14.0% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 13.3% | 62/100 |
| Operating margin volatility | 30.7% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 33.1% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 702 | 933 | 1,243 | 1,902 | 2,198 |
| Cost of revenue | – | – | – | – | 26 |
| Gross profit | – | – | – | – | 2,173 |
| Research & development | 771 | 877 | 877 | 805 | 1,522 |
| Selling, general & admin | 283 | 451 | 482 | 558 | 492 |
| Operating income | (460) | (536) | (268) | 218 | (700) |
| Interest expense | 64 | (53) | (22) | (18) | (38) |
| Pre-tax income | (419) | (690) | (520) | 261 | (702) |
| Income tax | (0.2) | 14 | 16 | 26 | 11 |
| Net income | (419) | (703) | (536) | 235 | (713) |
| Diluted EPS | −$5.15 | −$8.03 | −$5.80 | $2.34 | −$7.13 |
| Diluted shares (millions) | 81 | 88 | 92 | 108 | 100 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of Sarepta Therapeutics, Inc. are included in the Investor plan. Try free for 7 days →
−2.78 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026